A hardware-accelerated ecdlp with highperformance modular multiplication

Elliptic curve cryptography (ECC) has become a popular public key cryptography standard. The security of ECC is due to the difficulty of solving the elliptic curve discrete logarithm problem (ECDLP). In this paper, we demonstrate a successful attack on ECC over prime field using the Pollard rho algorithm implemented on a hardware-software cointegrated platform. We propose a high-performance architecture for multiplication over prime field using specialized DSP blocks in the FPGA. We characterize this architecture by exploring the design space to determine the optimal integer basis for polynomial representation and we demonstrate an efficient mapping of this design to multiple standard prime field elliptic curves. We use the resulting modular multiplier to demonstrate low-latency multiplications for curves secp112r1 and P-192. We apply our modular multiplier to implement a complete attack on secp112r1 using a Nallatech FSB-Compute platform with Virtex-5 FPGA. The measured performance of the resulting design is 114 cycles per Pollard rho step at 100 MHz, which gives 878 K iterations per second per ECC core. We extend this design to a multicore ECDLP implementation that achieves 14.05 M iterations per second with 16 parallel point addition cores

A Hardware-Accelerated ECDLP with High-Performance Modular Multiplication

Elliptic curve cryptography (ECC) has become a popular public key cryptography standard. The security of ECC is due to the difficulty of solving the elliptic curve discrete logarithm problem (ECDLP). In this paper, we demonstrate a successful attack on ECC over prime field using the Pollard rho algorithm implemented on a hardware-software cointegrated platform. We propose a high-performance architecture for multiplication over prime field using specialized DSP blocks in the FPGA. We characterize this architecture by exploring the design space to determine the optimal integer basis for polynomial representation and we demonstrate an efficient mapping of this design to multiple standard prime field elliptic curves. We use the resulting modular multiplier to demonstrate low-latency multiplications for curves secp112r1 and P-192. We apply our modular multiplier to implement a complete attack on secp112r1 using a Nallatech FSB-Compute platform with Virtex-5 FPGA. The measured performance of the resulting design is 114 cycles per Pollard rho step at 100 MHz, which gives 878 K iterations per second per ECC core. We extend this design to a multicore ECDLP implementation that achieves 14.05 M iterations per second with 16 parallel point addition cores

Prevention of recurrence of bacterial vaginosis using lactobacilli-containing vaginal tablets among women with HIV: a randomized, placebo-controlled, double-blinded phase IV trial

Objectives: The effectiveness of lactobacilli-containing vaginal tablets (VT) in bacterial vaginosis (BV) recurrence prevention among women infected with HIV treated with standard oral metronidazole in Pune, India was studied. Methods: Women infected with HIV with confirmed BV diagnosis (Nugent score ≥7 and Amsel criteria >3) were enrolled in a 12-month, double-blind, randomized, placebo-controlled, phase IV study between 2018 and 2021. After a standard course of oral metronidazole for 7 days (400 mg three times a day), women were randomly assigned to either lactobacilli-containing or placebo VT arms to receive VTs for 4 months. BV recurrence was assessed after the initial cure from BV. Results: Of the 464 women infected with HIV, 80 women with confirmed BV were enrolled. The retention was affected due to the COVID-19 pandemic (6-month retention rates 78%). The cure was seen in 85% and 93.5% of participants from the treatment and placebo arms, respectively, after four VT cycles. BV recurrence was seen in 41.4% and 44.8% in the treatment and placebo arm, respectively, with no significant difference in the two groups. Conclusion: The lactobacilli-containing VT was acceptable and safe; however, the addition of VT over standard oral metronidazole did not show any additional benefit in the prevention of BV recurrence in women infected with HIV, indicating the need for long-term randomized trials among them. Registered at Clinical Trials Registry- India, (CTRI) Number: CTRI/2018/04/01329

Development, validation and application of single molecule molecular inversion probe based novel integrated genetic screening method for 29 common lysosomal storage disorders in India

Abstract Background Current clinical diagnosis pathway for lysosomal storage disorders (LSDs) involves sequential biochemical enzymatic tests followed by DNA sequencing, which is iterative, has low diagnostic yield and is costly due to overlapping clinical presentations. Here, we describe a novel low-cost and high-throughput sequencing assay using single-molecule molecular inversion probes (smMIPs) to screen for causative single nucleotide variants (SNVs) and copy number variants (CNVs) in genes associated with 29 common LSDs in India. Results 903 smMIPs were designed to target exon and exon–intron boundaries of targeted genes (n = 23; 53.7 kb of the human genome) and were equimolarly pooled to create a sequencing library. After extensive validation in a cohort of 50 patients, we screened 300 patients with either biochemical diagnosis (n = 187) or clinical suspicion (n = 113) of LSDs. A diagnostic yield of 83.4% was observed in patients with prior biochemical diagnosis of LSD. Furthermore, diagnostic yield of 73.9% (n = 54/73) was observed in patients with high clinical suspicion of LSD in contrast with 2.4% (n = 1/40) in patients with low clinical suspicion of LSD. In addition to detecting SNVs, the assay could detect single and multi-exon copy number variants with high confidence. Critically, Niemann-Pick disease type C and neuronal ceroid lipofuscinosis-6 diseases for which biochemical testing is unavailable, could be diagnosed using our assay. Lastly, we observed a non-inferior performance of the assay in DNA extracted from dried blood spots in comparison with whole blood. Conclusion We developed a flexible and scalable assay to reliably detect genetic causes of 29 common LSDs in India. The assay consolidates the detection of multiple variant types in multiple sample types while having improved diagnostic yield at same or lower cost compared to current clinical paradigm